Pfizer announces its future strategy in the Egyptian market

Pfizer Egypt for Pharmaceutical and Biopharmaceuticals organized a press conference to share the company's latest business update for 2022 and its strategy in Egypt in the coming years, highlighting its commitment to growing its presence in the Egyptian market in the next few years. During the press conference, Pfizer announced its success in providing the latest treatments and medicines to 7 million patients in Egypt, and its goal to reach 7.6 million patients by the end of this year. The company also aims to launch 7 new products in Egypt in 2023 most of them for treating Cancerous diseases.

This came on the sidelines of the inauguration of Pfizer’s new office in Cairo, which comes as part of the company’s strategy to provide first-in-class and innovative treatments based on the latest R&D methods in Egypt. H.E. Ambassador Daniel Rubinstein, US Chargé d'Affairs to Egypt, Mr. Patrick van der Loo, Pfizer Regional President for the Middle East, Russia and Africa region (MERA), and Dr. Ahmed El-Shazly, Pfizer Country Manager for Egypt and Sudan, attended the press conference in addition to media representatives.